Recent clinical trials demonstrated that a specific subset of non–small cell lung cancer (NSCLC) patients exhibit a clear response to PD-1 blockade (1–3) and that the benefit of this treatment is greater than that of platinum doublet chemotherapy when the level of PD-L1 expression in tumors is higher (4). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.